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The World Health Organization identified antimicrobial resistance (AMR) as one of the greatest 
threats to human health. Drug-resistant infections already kill hundreds of thousands a year 
globally, and by 2050 that figure could be more than 10 million (amr.review.org). Of particular 
concern is the mounting prevalence of infections caused by multidrug resistant (MDR) Gram-
negative bacteria. Although Escherichia coli is the most common cause of invasive Gram-
negative infections, the most significant challenge comes from Klebsiella pneumoniae.  The 
percentage of isolates resistant to last generation antibiotics continues to increase worldwide. 
In fact, the isolation of Klebsiella strains resistant to “last resort” antimicrobials has significantly 
narrowed, or in some settings completely removed, the therapeutic options for the treatment 
of Klebsiella infections. To further complicate this scenario, recent population genomic studies 
have shown that virulent and MDR resistant clones have access to a diverse mobile pool of 
virulence and antimicrobial resistance genes of high penetrance1, 2 hence making possible the 
emergence of an extremely drug-resistant hypervirulent K. pneumoniae clone capable of 
causing untreatable infections in healthy individuals. It is then not surprising that MDR K. 
pneumoniae has been singled out as an “urgent threat to human health” by several institutions 
including the UK government, the CDC and the WHO. However, and despite the clinical 
relevance, there is still scant evidence on K. pneumoniae pathogenesis at the molecular and 
cellular level. Therefore, the development of new therapeutic strategies requires a better 
understanding of K. pneumoniae pathophysiology in the context of the complex interactions 
between bacterial pathogens and their hosts.  
In this issue of Virulence, Lee et al3 investigate the relationship between glycemic control and 
the onset of Klebsiella-triggered invasive infections. This study is of clinical relevance given 
the increasing number of Klebsiella disseminated infections in patients with underlying 
conditions such as diabetes and liver disease, mostly in East Asian countries. However, the 
high prevalence of obesity worldwide, which is associated with risks of developing type 2 
diabetes, anticipates an overall increase of this type of Klebsiella invasive infections 
worldwide. Unfortunately, the clinical data presented in this work further confirms previous 
studies demonstrating a correlation between community-acquired Klebsiella disseminated 
infections and type 2 diabetes mellitus4. Further analysis of the clinical data by Lee et al3 
revealed a remarkable correlation between disseminated infections and patients with poor 
glycemic control compared with diabetic patients with good glycemic control. Interestingly, 
previous studies have suggested that poor glycemic control impairs neutrophils phagocytosis 
of K. pneumoniae capsule serotypes K1 and K25. Taken into consideration the important role 
of neutrophils in Klebsiella clearance, this reduced phagocytosis may explain the increased 
disseminated Klebsiella infections in these patients. In this study, Lee et al decided to 
investigate the other side of the coin: whether poor glycemic control, in other words high 
glucose levels in blood, may affect the pathogenicity of Klebsiella. Not surprisingly, they chose 
to explore the effect of high glucose on the single most important virulence factor of K. 
pneumoniae, the capsule polysaccharide6. Capsule mutants are attenuated in the pneumonia 
mouse model and in the Galleria mellonella one6, 7.The capsule polysaccharide protects 
Klebsiella against the bactericidal action of complement and antimicrobial peptides8, 9, limits 
the activation of inflammatory responses10-12, and reduces phagocytosis by neutrophils and 
even amoebas13, 14. In this work, Lee et al3 conclusively demonstrate that high glucose levels, 
but not high glycerol ones, up regulate the transcription of the cps operon with a concomitant 
increase in the levels of surface exposed polysaccharide. Further studies are required to 
decipher the molecular basis of this upregulation. In fact, capsule regulation in Klebsiella is 
still poorly understood. As anticipated, glucose-induced high capsule levels were associated 
with a further increased in Klebsiella resistance to neutrophils phagocytosis and whole blood 
leukocyte killing. Since previous studies have shown that there is a correlation between the 
capsule levels and the resistance to antimicrobial peptides and the induction of inflammatory 
responses15-17, it is tempting to postulate that poor glycemic control enhances capsule-
dependent Klebsiella anti-immune mechanisms and, therefore, the virulence of the pathogen. 
However sounded this hypothesis, further studies are warranted to provide a global view of 
Klebsiella transcriptome when grown in high glucose to investigate, for example, whether the 
expressions of other known Klebsiella virulence factors such as the siderophores, the 
lipopolysaccharide and the OmpA outer membrane protein are also affected12, 16, 18-22. 
Nevertheless, the time is ripe to carry out these studies in vivo using well established obesity 
or diabetes mellitus animal models thereby allowing a better understanding of Klebsiella 
biology in the context of the host. This fundamental knowledge is absolutely essential not only 
to inform the management of diabetic patients but also to develop new therapeutics based on 
new targets and approaches.  
In conclusion, this study by Lee et al establishes that type 2 diabetes mellitus with poor 
glycemic control is a risk factor for Klebsiella disseminated infections. The reported in vitro 
data indicates that high glucose may enhance capsule-dependent evasion of the immune 
system hence contributing to develop disseminated infections. Taken together, this means 
that therapeutics targeting Klebsiella capsule, or interfering with capsule-mediated anti-
immune mechanisms, may be a potential strategy to fight Klebsiella infections. 
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